The use of PARP inhibitors as maintenance therapy in ovarian carcinosarcoma: A case series.

Objective: Carcinosarcoma an aggressive subtype of ovarian cancer. While treatment consists primarily of cytoreductive surgery followed by platinum-based chemotherapy, maintenance therapy can also be considered. Limited data exists on the use of poly ADP-ribose polymerase (PARP) inhibitors in ovarian carcinosarcoma, though this has been anecdotally successful among a small number of patients. In this case series, we present four patients with advanced or recurrent ovarian carcinosarcoma who were successfully treated with PARP inhibitors. Methods: This case series included patients ages 18 or older who were diagnosed with ovarian carcinosarcoma and received maintenance therapy with a PARP inhibitor. Patient demographic and oncologic data was extracted. Cases were presented in detail and descriptive statistics were performed. A literature review was conducted to identify additional published case reports. Results: Four patients from our institution were identified upon review of the electronic medical record. Age range at time of diagnosis was 47 to 74. Of the four patients, three (75 %) were treated in the upfront setting and one (25 %) was treated in the recurrent setting. Two patients were positive for homologous recombination deficiency, and another was positive for a Conclusions: We present a series of patients with ovarian carcinosarcoma who were treated with PARP inhibitors at our institution and saw clinically meaningful benefits, both in the upfront and recurrent setting.